Inhibikase Therapeutics, Inc 10-K for FY2022
Inhibikase Therapeutics, Inc. (IKT)
10-K
2023-03-31
For: 2022-12-31
View Original
Added on
April 07, 2026
About this 10-K
Inhibikase Therapeutics, Inc filed this 10-K on March 31, 2023, covering the fiscal year ended December 31, 2022 (FY2022).
Headline figures
Fiscal year ended December 31, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $123.44K
- down 96.0% from $3.1M a year earlier
- Net loss
- $18.05M
- compared with a net loss of $14.79M a year earlier
- Diluted EPS
- -$0.72
- compared with -$0.81 a year earlier